Save information for later
Sign Up

Learn About Immune Thrombocytopenic Purpura (ITP)

What is the definition of Immune Thrombocytopenic Purpura (ITP)?

Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting.

What are the causes of Immune Thrombocytopenic Purpura (ITP)?

The genetic cause of immune thrombocytopenia is unclear. This condition occurs when the body's own immune system malfunctions and attacks the body's tissues and organs (autoimmunity). Normally, the immune system produces proteins called antibodies, which attach to specific foreign particles and germs, marking them for destruction. In immune thrombocytopenia, the immune system abnormally destroys platelets and makes fewer platelets than normal. People with immune thrombocytopenia produce antibodies that attack normal platelets. The platelets are destroyed and eliminated from the body, resulting in a shortage of these cells in affected individuals. Some of these antibodies also affect the cells in the bone marrow that produce platelets (known as megakaryocytes), which leads to a decrease in platelet production, further reducing the number of platelets in the blood.

How prevalent is Immune Thrombocytopenic Purpura (ITP)?

The incidence of immune thrombocytopenia is approximately 4 per 100,000 children and 3 per 100,000 adults. In adults with immune thrombocytopenia, women are affected more often than men.

Is Immune Thrombocytopenic Purpura (ITP) an inherited disorder?

Immune thrombocytopenia and other autoimmune disorders can run in families, but the inheritance pattern is usually unknown. People with a first-degree relative (such as a parent or sibling) with immune thrombocytopenia likely have an increased risk of developing the disorder themselves.

Who are the top Immune Thrombocytopenic Purpura (ITP) Local Doctors?
Elite in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology
Elite in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology
1120 15th St, 
Augusta, GA 
Languages Spoken:
English

Cindy Neunert is a Pediatric Hematologist Oncology provider in Augusta, Georgia. Dr. Neunert is rated as an Elite provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Sickle Cell Disease, Multisystem Inflammatory Syndrome in Children (MIS-C), and Splenectomy.

Elite in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology
Elite in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology
525 E 68th St # P-695, 
New York, NY 
Languages Spoken:
English

James Bussel is a Pediatric Hematologist Oncology provider in New York, New York. Dr. Bussel is rated as an Elite provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Anemia, Hemolysis, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Immune Thrombocytopenic Purpura (ITP)
Elite in Immune Thrombocytopenic Purpura (ITP)
Du Cane Road, 
London, ENG, GB 

Nichola Cooper practices in London, United Kingdom. Ms. Cooper is rated as an Elite expert by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Adult Immune Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Purpura, Splenectomy, and Kidney Transplant.

What are the latest Immune Thrombocytopenic Purpura (ITP) Clinical Trials?
A Phase 1/2 Clinical Study of CM336 Injection in Patients With Relapsed or Refractory Autoimmune Cytopenia

Summary: To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Summary: The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment perio...

Who are the sources who wrote this article ?

Published Date: June 01, 2017
Published By: National Institutes of Health